Year archive

Innovent Biologics, Inc. — 2026 filings

All 21 regulatory filings released by Innovent Biologics, Inc. (1801) in 2026, sourced directly from the official regulator.

21 Filings

2026 Period

2026 filings (21)

Filing	Released	Lang
Form of Proxy for use at the Annual General Meeting to be held on Wednesday, June 24, 2026 Proxy Solicitation & Information Statement	2026-05-29	English
NOTICE OF ANNUAL GENERAL MEETING AGM Information	2026-05-29	English
(1) PROPOSED GRANTING OF GENERAL MANDATES TO BUY BACK SHARES AND TO ISSUE NEW SHARES, (2) PROPOSED RE-ELECTION OF THE RETIRING DIRECTORS, (3) PROPOSED RE-APPOINTMENT OF THE EXTERNAL AUDITOR, AND (4) N Proxy Solicitation & Information Statement	2026-05-29	English
INSIDE INFORMATION ANNOUNCEMENT - ENTERING INTO GLOBAL STRATEGIC COLLABORATION WITH PFIZER TO ACCELERATE DEVELOPMENT OF INNOVATIVE ONCOLOGY MEDICINES Regulatory Filings	2026-05-29	English
DISCLOSEABLE TRANSACTIONS - ACQUISITIONS AND SUBSCRIPTION OF INVESTMENT NOTES AND CLARIFICATION IN RELATION TO GRANT OF SHARE OPTIONS AND RESTRICTED SHARES Regulatory Filings	2026-05-22	English
VOLUNTARY ANNOUNCEMENT - NMPA APPROVAL FOR TYVYT (SINTILIMAB INJECTION) IN COMBINATION WITH ELUNATE (FRUQUINTINIB) FOR THE TREATMENT OF PATIENTS WITH LOCALLY ADVANCED OR METASTATIC RENAL CELL CARCINOM Regulatory Filings	2026-05-21	English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 April 2026 Regulatory Filings	2026-05-07	English
INSIDE INFORMATION ANNOUNCEMENT - UPDATE ON THE COMPANY'S PRODUCT REVENUE IN THE FIRST QUARTER OF 2026 Earnings Release Q1 2026	2026-04-30	English
2025 ENVIRONMENTAL, SOCIAL AND GOVERNANCE REPORT Environmental & Social Information	2026-04-28	English
2025 ANNUAL REPORT Annual Report FY 2025	2026-04-28	English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 March 2026 Share Issue/Capital Change	2026-04-09	English
GRANT OF SHARE OPTIONS AND RESTRICTED SHARES Share Issue/Capital Change	2026-03-31	English
ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED 31 DECEMBER 2025 Earnings Release FY 2025	2026-03-26	English
EFFECTIVENESS OF THE STRATEGIC COLLABORATION WITH LILLY AND CLARIFICATION Regulatory Filings	2026-03-25	English
DATE OF BOARD MEETING Report Publication Announcement	2026-03-12	English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 28 February 2026 Share Issue/Capital Change	2026-03-05	English
VOLUNTARY ANNOUNCEMENT - JAYPIRCA (PIRTOBRUTINIB) APPROVED IN CHINA FOR THE TREATMENT OF RELAPSED OR REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA OR SMALL LYMPHOCYTIC LYMPHOMA Regulatory Filings	2026-02-27	English
INSIDE INFORMATION ANNOUNCEMENT - ENTERING INTO STRATEGIC COLLABORATION WITH LILLY TO DEVELOP NEW MEDICINES GLOBALLY IN ONCOLOGY AND IMMUNOLOGY M&A Activity	2026-02-08	English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 January 2026 Share Issue/Capital Change	2026-02-05	English
INSIDE INFORMATION ANNOUNCEMENT - ROBUST GROWTH ACHIEVED IN PRODUCT REVENUE IN THE YEAR AND THE FOURTH QUARTER OF 2025 Earnings Release FY 2025	2026-02-04	English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 December 2025 Regulatory Filings	2026-01-07	English

Filings by year

2026 21 filings
2025 56 filings
2024 63 filings
2023 46 filings
2022 58 filings
2021 60 filings
2020 65 filings
2019 54 filings
2018 26 filings